NCT01894776View on ClinicalTrials.gov

A Drug Interaction Study Investigating the Effect of Rifabutin on the Pharmacokinetics of Maraviroc

PHASE1CompletedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

June 30, 2013

Primary Completion Date

December 31, 2013

Study Completion Date

February 28, 2015

Conditions
HIV InfectionHIV-1 InfectionMycobacterium Avium Complex (MAC)
Interventions
DRUG

Rifabutin

Substance: Rifabutin Daily dose: oral, 300 mg once daily (8:00 am) for 10 days

DRUG

Maraviroc

Substance maraviroc daily dose 300 mg twice daily (8:00 am and 8:00 pm) for 15 days

Trial Locations (1)

K1H 8L6

The Ottawa Hospital -General Campus, Ottawa

Sponsors

Collaborators (1)

Pfizer
All Listed Sponsors
collaborator

Pfizer

INDUSTRY

lead

Ottawa Hospital Research Institute

OTHER